Developer docs
API playgroundTry for free, no card

Search company profiles

Vico Therapeutics

Full company profile

uuid0000bor

Namestring
Vico Therapeutics
Legal namestring
Vico Therapeutics B.V.
Websiteurl
vicotx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vico Therapeutics B.V. is a clinical-stage genetic medicines company founded in 2019 and headquartered in Leiden, the Netherlands. It develops antisense oligonucleotide (ASO) therapies that target the CAG trinucleotide repeat expansion mutation underlying polyglutamine (polyQ) diseases — a group of nine rare neurodegenerative disorders including Huntington's disease (HD) and the spinocerebellar ataxias SCA1 and SCA3. The company is currently pre-revenue.

The company's core platform, VICOMER, is an oligonucleotide-based RNA modulation engine that designs ASOs capable of inhibiting translation, modulating splicing, editing RNA, degrading transcripts, or activating expression depending on the genetic defect targeted. Its lead clinical candidate, VO659, is an allele-preferential ASO designed to reduce mutant huntingtin protein while preserving wild-type protein function, and is positioned as the only clinical-stage candidate directly targeting the pathogenic CAG repeat expansion shared across all nine polyQ diseases. VO659 has demonstrated a 38% reduction in cerebrospinal fluid mutant huntingtin (mHTT) and a 2.5% reduction in neurofilament light chain (Nf-L) at four months, with a long half-life supporting potential twice-yearly intrathecal dosing. Beyond VO659, the pipeline includes preclinical/early programs for Rett syndrome (MECP2), familial Alzheimer's disease, and three undisclosed CNS programs.

Vico's business model is pre-commercial R&D funded by venture capital. To date it has raised approximately €65.8 million (~$84 million) across Series A (~$31M, July 2020) and Series B (€54M in January 2024 plus an €11.5M second closing in June 2024). The lead asset is being advanced in a multi-country European Phase 1/2a basket trial in HD, SCA1, and SCA3 (target enrollment ~71 participants, NCT05822908), with US expansion enabled by FDA IND clearance in February 2026. The company holds both FDA and EMA Orphan Drug Designations for VO659 in Huntington's disease. Customers at the development stage are clinical trial investigators and specialized neurology centers, with the end market being patients with rare neurodegenerative disorders — a population with no approved disease-modifying therapies.

Short descriptiontext

Vico Therapeutics is a clinical-stage Dutch biotech developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation causing polyglutamine diseases, with lead candidate VO659 in Phase 1/2a trials for Huntington's disease and spinocerebellar ataxias.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapies, RNA modulating therapeutics, polyglutamine disease treatment, rare neurological drug development, genetic medicine platform
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Neurological Genetic Medicines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Pipeline Development Stage
TypeSubscription Recurring
Description

Vico Therapeutics is a clinical-stage genetic medicines company that is pre-revenue. The company is funded through venture capital financing rounds (Series B) to advance its pipeline of ASO therapies. No commercialized products or revenue-generating activities are described.

vicotx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA-modulating therapies for rare genetic neurological diseases. Its lead investigational therapy, VO659, is an allele-preferential ASO designed to directly target the CAG repeat expansion mutation that causes all nine known polyglutamine diseases, including Huntington's disease, spinocerebellar ataxia type 1 (SCA1), and spinocerebellar ataxia type 3 (SCA3). The company also operates the VICOMER discovery platform and additional pipeline programs in Rett syndrome, familial Alzheimer's disease, and undisclosed CNS indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 38% reduction in cerebrospinal fluid mutant huntingtin protein (CSF mHTT) and 2.5% reduction in CSF Nf-L in HD patients dosed with VO659 at four months
+3 more records
Product overview1 text field

Vico Therapeutics is a clinical-stage genetic medicines company with a unified therapeutic platform focused on RNA-modulating antisense oligonucleotide (ASO) therapies for rare genetic neurological diseases. The company's lead product is VO659, currently in Phase 1/2a clinical development for Huntington's disease, SCA1, and SCA3. The VICOMER platform serves as the foundational technology enabling the design of fit-for-purpose ASOs for various genetic defects. The pipeline includes programs for Rett Syndrome and Familial Alzheimer's Disease, plus three undisclosed CNS programs.

Product and service1 record
1VO659
CategoryAntisense oligonucleotide (ASO) investigational therapy
Description

VO659 is Vico's lead allele-preferential antisense oligonucleotide (ASO) investigational therapy designed to directly target the CAG repeat expansion mutation that causes all nine known polyglutamine diseases. It selectively reduces disease-causing mutant huntingtin (HTT), ATXN1, and ATXN3 proteins while preserving wild-type protein function, and is currently in Phase 1/2a clinical development for Huntington's disease, SCA1, and SCA3. The therapy is administered intrathecally and is being explored at a long-acting twice-annual dosing regimen. VO659 has received both FDA and EMA Orphan Drug Designation for Huntington's disease.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI Foundation is a nonprofit biotech that collaborates with Vico on Huntington's disease research. Vico's CSO and CMO presented VO659 data at CHDI's 21st Annual HD Therapeutics Conference. CHDI supports HD therapeutic development through scientific collaboration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vico presented positive interim Phase 1/2a clinical data at the EHDN & Enroll-HD 2024 meeting, highlighting first clinical data for VO659 in Huntington's disease treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ASO developer with multiple allele-selective Huntington's disease programs (WVE-003 targeting mHTT, WVE-004 for ALS). Directly comparable to Vico as both pursue allele-preferential ASO approaches in CNS, competing for similar patient populations, KOL relationships, and partnership economics.

TypeBroad incumbent
Description

Developed tominersen, the most advanced huntingtin-lowering ASO program that halted in Phase 3. As a broad incumbent in CNS and rare disease with substantial resources, Roche represents both the benchmark and the cautionary tale for VO659, with potential interest in acquiring or partnering with Vico given the mechanism's allele-preferential differentiation.

TypeDirect peer
Description

Developing AMT-130, an AAV gene therapy for Huntington's disease currently in clinical trials. Competes with Vico in the same disease space with a different modality (gene therapy vs. ASO), targeting the same HTT-lowering mechanism and similar clinical investigator networks.

TypeDirect peer
Description

Was developing ASO therapies targeting the CAG repeat expansion in polyQ diseases, directly overlapping Vico's lead mechanism. Although Triplet shifted strategic direction, it represents the closest historical peer in the specific polyQ repeat-targeting approach.

TypeDirect peer
Description

Clinical-stage company developing antisense oligonucleotides (TANGO platform) for CNS genetic diseases including Dravet syndrome and ADOA. Comparable ASO modality, CNS focus, rare disease positioning, and similar clinical-stage development trajectory.

TypeDirect peer
Description

Clinical-stage Dutch biotech developing Axiomer RNA editing oligonucleotide platform for genetic diseases. Same Leiden/Netherlands origin, comparable oligonucleotide modality, and similar rare disease CNS focus.

TypeBroad incumbent
Description

The leading antisense oligonucleotide platform company with multiple approved and clinical-stage ASO drugs (Spinraza, Tegsedi, Waylivra). Represents the gold standard ASO platform with extensive CMC, regulatory, and clinical infrastructure relevant to Vico's ASO development.

8Locanabio
TypeEmerging player
Description

RNA-targeted gene therapy company where Vico's CEO Micah Mackison previously served as CBO. Operates in the same RNA-modulation and genetic neurological disease space, providing a comparable development-stage peer and a connection point in management.

TypeBroad incumbent
Description

CNS-focused biotech with Huntington's disease programs in development alongside its approved Zurzuvae. Comparable in CNS rare disease focus and neurology KOL relationships, though Sage pursues small molecules rather than ASOs.

TypeBroad incumbent
Description

Rare disease biotech where Vico's CSO Nicole Datson previously led drug discovery. BioMarin has CNS rare disease programs and substantial ASO/oligonucleotide experience through partnerships, providing an established incumbent comparable to Vico's specialty rare neurology focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vico Therapeutics

Rare Neurological Genetic Medicinesvicotx.com

Vico Therapeutics is a clinical-stage Dutch biotech developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation causing polyglutamine diseases, with lead candidate VO659 in Phase 1/2a trials for Huntington's disease and spinocerebellar ataxias.

What Vico Therapeutics does

Vico Therapeutics B.V. is a clinical-stage genetic medicines company founded in 2019 and headquartered in Leiden, the Netherlands. It develops antisense oligonucleotide (ASO) therapies that target the CAG trinucleotide repeat expansion mutation underlying polyglutamine (polyQ) diseases — a group of nine rare neurodegenerative disorders including Huntington's disease (HD) and the spinocerebellar ataxias SCA1 and SCA3. The company is currently pre-revenue.

The company's core platform, VICOMER, is an oligonucleotide-based RNA modulation engine that designs ASOs capable of inhibiting translation, modulating splicing, editing RNA, degrading transcripts, or activating expression depending on the genetic defect targeted. Its lead clinical candidate, VO659, is an allele-preferential ASO designed to reduce mutant huntingtin protein while preserving wild-type protein function, and is positioned as the only clinical-stage candidate directly targeting the pathogenic CAG repeat expansion shared across all nine polyQ diseases. VO659 has demonstrated a 38% reduction in cerebrospinal fluid mutant huntingtin (mHTT) and a 2.5% reduction in neurofilament light chain (Nf-L) at four months, with a long half-life supporting potential twice-yearly intrathecal dosing. Beyond VO659, the pipeline includes preclinical/early programs for Rett syndrome (MECP2), familial Alzheimer's disease, and three undisclosed CNS programs.

Vico's business model is pre-commercial R&D funded by venture capital. To date it has raised approximately €65.8 million (~$84 million) across Series A (~$31M, July 2020) and Series B (€54M in January 2024 plus an €11.5M second closing in June 2024). The lead asset is being advanced in a multi-country European Phase 1/2a basket trial in HD, SCA1, and SCA3 (target enrollment ~71 participants, NCT05822908), with US expansion enabled by FDA IND clearance in February 2026. The company holds both FDA and EMA Orphan Drug Designations for VO659 in Huntington's disease. Customers at the development stage are clinical trial investigators and specialized neurology centers, with the end market being patients with rare neurodegenerative disorders — a population with no approved disease-modifying therapies.

Vico Therapeutics firmographics

Firmographics
Name
Vico Therapeutics
Legal name
Vico Therapeutics B.V.
Website
https://vicotx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Vico Therapeutics is a clinical-stage Dutch biotech developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation causing polyglutamine diseases, with lead candidate VO659 in Phase 1/2a trials for Huntington's disease and spinocerebellar ataxias.
Ownership category
akta.pro rank

Vico Therapeutics industry classification

Industry
Product category
Rare Neurological Genetic Medicines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapies
  • RNA modulating therapeutics
  • Polyglutamine disease treatment
  • Rare neurological drug development
  • Genetic medicine platform

Where Vico Therapeutics is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Vico Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue / Pipeline Development Stage: Vico Therapeutics is a clinical-stage genetic medicines company that is pre-revenue. The company is funded through venture capital financing rounds (Series B) to advance its pipeline of ASO therapies. No commercialized products or revenue-generating activities are described.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Vico Therapeutics product offering

Product offering

Core offering

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA-modulating therapies for rare genetic neurological diseases. Its lead investigational therapy, VO659, is an allele-preferential ASO designed to directly target the CAG repeat expansion mutation that causes all nine known polyglutamine diseases, including Huntington's disease, spinocerebellar ataxia type 1 (SCA1), and spinocerebellar ataxia type 3 (SCA3). The company also operates the VICOMER discovery platform and additional pipeline programs in Rett syndrome, familial Alzheimer's disease, and undisclosed CNS indications.

Product overview

Vico Therapeutics is a clinical-stage genetic medicines company with a unified therapeutic platform focused on RNA-modulating antisense oligonucleotide (ASO) therapies for rare genetic neurological diseases. The company's lead product is VO659, currently in Phase 1/2a clinical development for Huntington's disease, SCA1, and SCA3. The VICOMER platform serves as the foundational technology enabling the design of fit-for-purpose ASOs for various genetic defects. The pipeline includes programs for Rett Syndrome and Familial Alzheimer's Disease, plus three undisclosed CNS programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • VO659 VO659 is Vico's lead allele-preferential antisense oligonucleotide (ASO) investigational therapy designed to directly target the CAG repeat expansion mutation that causes all nine known polyglutamine diseases. It selectively reduces disease-causing mutant huntingtin (HTT), ATXN1, and ATXN3 proteins while preserving wild-type protein function, and is currently in Phase 1/2a clinical development for Huntington's disease, SCA1, and SCA3. The therapy is administered intrathecally and is being explored at a long-acting twice-annual dosing regimen. VO659 has received both FDA and EMA Orphan Drug Designation for Huntington's disease.

Quantifiable outcome

  • 38% reduction in cerebrospinal fluid mutant huntingtin protein (CSF mHTT) and 2.5% reduction in CSF Nf-L in HD patients dosed with VO659 at four months
  • +3 more outcomes

Companies that use Vico Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Vico Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vico Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CHDI FoundationcoreStrategic or Co-development PartnerCHDI Foundation is a nonprofit biotech that collaborates with Vico on Huntington's disease research. Vico's CSO and CMO presented VO659 data at CHDI's 21st Annual HD Therapeutics Conference. CHDI supports HD therapeutic development through scientific collaboration.
  • European Huntington's Disease Network (EHDN)coreStrategic or Co-development PartnerVico presented positive interim Phase 1/2a clinical data at the EHDN & Enroll-HD 2024 meeting, highlighting first clinical data for VO659 in Huntington's disease treatment.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Vico Therapeutics competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Clinical-stage ASO developer with multiple allele-selective Huntington's disease programs (WVE-003 targeting mHTT, WVE-004 for ALS). Directly comparable to Vico as both pursue allele-preferential ASO approaches in CNS, competing for similar patient populations, KOL relationships, and partnership economics.
  • uniQure: Developing AMT-130, an AAV gene therapy for Huntington's disease currently in clinical trials. Competes with Vico in the same disease space with a different modality (gene therapy vs. ASO), targeting the same HTT-lowering mechanism and similar clinical investigator networks.
  • Triplet Therapeutics: Was developing ASO therapies targeting the CAG repeat expansion in polyQ diseases, directly overlapping Vico's lead mechanism. Although Triplet shifted strategic direction, it represents the closest historical peer in the specific polyQ repeat-targeting approach.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotides (TANGO platform) for CNS genetic diseases including Dravet syndrome and ADOA. Comparable ASO modality, CNS focus, rare disease positioning, and similar clinical-stage development trajectory.
  • ProQR Therapeutics: Clinical-stage Dutch biotech developing Axiomer RNA editing oligonucleotide platform for genetic diseases. Same Leiden/Netherlands origin, comparable oligonucleotide modality, and similar rare disease CNS focus.

Broad incumbents

  • Roche (Genentech): Developed tominersen, the most advanced huntingtin-lowering ASO program that halted in Phase 3. As a broad incumbent in CNS and rare disease with substantial resources, Roche represents both the benchmark and the cautionary tale for VO659, with potential interest in acquiring or partnering with Vico given the mechanism's allele-preferential differentiation.
  • Ionis Pharmaceuticals: The leading antisense oligonucleotide platform company with multiple approved and clinical-stage ASO drugs (Spinraza, Tegsedi, Waylivra). Represents the gold standard ASO platform with extensive CMC, regulatory, and clinical infrastructure relevant to Vico's ASO development.
  • Sage Therapeutics: CNS-focused biotech with Huntington's disease programs in development alongside its approved Zurzuvae. Comparable in CNS rare disease focus and neurology KOL relationships, though Sage pursues small molecules rather than ASOs.
  • BioMarin Pharmaceutical: Rare disease biotech where Vico's CSO Nicole Datson previously led drug discovery. BioMarin has CNS rare disease programs and substantial ASO/oligonucleotide experience through partnerships, providing an established incumbent comparable to Vico's specialty rare neurology focus.

Emerging players

  • Locanabio: RNA-targeted gene therapy company where Vico's CEO Micah Mackison previously served as CBO. Operates in the same RNA-modulation and genetic neurological disease space, providing a comparable development-stage peer and a connection point in management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vico Therapeutics social profiles

Digital presence

Vico Therapeutics compliance and trust

Trust signal

Compliance2 records

Vico Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vico Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Vico Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vico Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vico Therapeutics

What does Vico Therapeutics do?

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA-modulating therapies for rare genetic neurological diseases. Its lead investigational therapy, VO659, is an allele-preferential ASO designed to directly target the CAG repeat expansion mutation that causes all nine known polyglutamine diseases, including Huntington's disease, spinocerebellar ataxia type 1 (SCA1), and spinocerebellar ataxia type 3 (SCA3). The company also operates the VICOMER discovery platform and additional pipeline programs in Rett syndrome, familial Alzheimer's disease, and undisclosed CNS indications.

Is Vico Therapeutics a public or private company?

Vico Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vico Therapeutics founded?

Vico Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Vico Therapeutics based?

Vico Therapeutics is headquartered in Leiden, Netherlands, in the Europe region.

How does Vico Therapeutics make money?

One revenue line is on record: pre-revenue / Pipeline Development Stage.

Who are Vico Therapeutics's main competitors?

Direct peers on record are Wave Life Sciences, uniQure, Triplet Therapeutics, Stoke Therapeutics and ProQR Therapeutics. Broad incumbents are Roche (Genentech), Ionis Pharmaceuticals, Sage Therapeutics and BioMarin Pharmaceutical. Locanabio is listed as an emerging player.

Does Vico Therapeutics have an API?

No public API is recorded for Vico Therapeutics.

What industry is Vico Therapeutics in?

Vico Therapeutics's product category is Rare Neurological Genetic Medicines. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogVico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1Vico Therapeutics announced that patient dosing has commenced in an expanded cohort using a twice-annual regimen of VO659 in its Phase 1/2a clinical trial for Huntington's disease, spinocerebellar ataxia type 3, and type 1 across multiple European countries. The company reported that prior dosing achieved a 38% reduction in cerebrospinal fluid mutant huntingtin protein and a 2.5% reduction in neurofilament light chain with no serious adverse events, while also receiving FDA Investigational New Drug clearance to expand the trial to the United States later this year. Vico's Chief Scientific Officer and Chief Medical Officer are presenting additional data on VO659's mechanism of action and clinical trial results at CHDI's 21st Annual HD Therapeutics Conference.Business Wire BlogSeroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)Seroba and Kurma Partners announced the completion of a Series B financing round of Vico Therapeutics, raising €65.8 million ($70.7 million) to support clinical development. The funding aims to advance therapies for severe neurological diseases, including spinocerebellar ataxia and Huntington’s disease.FinSMEsVico Therapeutics Raises EUR11.5M in Additional Series BVico Therapeutics raised EUR 11.5 million in the second closing of its Series B funding round, bringing the total raised to €65.8 million. The company plans to use these funds to advance its lead clinical program and develop a portfolio of novel antisense oligonucleotides for severe neurological diseases.Silicon CanalsLeiden-based Vico Therapeutics raises €11.5MVico Therapeutics, a Leiden-based clinical-stage genetic medicines company, raised €11.5M in a second closing of a Series B financing round led by Seroba and Kurma Partners. This funding adds to a previous €54M raised earlier this year, bringing the total Series B financing to €65.8M, which will support the development of therapies for severe neurological diseases. The investment will enhance Vico's ability to advance its RNA-modulating therapies for conditions like Huntington's disease and spinocerebellar ataxia.Business Wire BlogSeroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)Seroba and Kurma Partners completed the second closing of Vico Therapeutics' Series B, adding €11.5 million to an existing €54.3 million, totaling €65.8 million ($70.7 million). The funding supports Vico's lead program VO659 in a Phase 1/2a study for spinocerebellar ataxia and Huntington's disease.NewnexEuropean Startups funded recently - Newnex FortnightOver the past two weeks, European startups have collectively secured over $1.6 billion in funding, with significant contributions coming from various investors across multiple countries. Notable rounds include Patchworks in the UK raising £1.75 million, Vico Therapeutics in the Netherlands raising €54 million, and Electra in France raising €304 million to expand its charging station network. This surge in funding highlights a strong interest in innovative technologies and sustainable solutions in Europe.Daily Medical NewsVico receives $60M funding to support novel therapy for neurodegenerative conditionsVico Therapeutics raised $60 million in Series B financing to support a phase 1/2 clinical trial of its lead candidate VO659 for spinocerebellar ataxia types 1 and 3 and Huntington's disease. The trial will assess safety and tolerability of intrathecal VO659, with the first patient expected in April. The funding will also support research to expand studies in other genetic neurological diseases.FinSMEsVico Therapeutics Raises $60M in Series B FinancingVico Therapeutics raised $60M in Series B funding led by Ackermans & van Haaren, with participation from Droia Ventures, EQT Life Sciences, and Kurma Partners. The company will use the funds to support its Phase 1/2a clinical trial of VO659 for spinocerebellar ataxia and Huntington's disease. Jeroen Vangindertael will join the board.PR NewswireVico Therapeutics beruft Scott Schobel, MD zum Chief Medical OfficerVico Therapeutics B.V., a neurology-focused genetic medicine company based in Leiden, Netherlands, appointed Scott Schobel, MD as Chief Medical Officer. Dr. Schobel brings 10 years of experience from Roche, where he led the Tominersen clinical development program for Huntington's disease. In his new role, he will advance VO659 into clinical trials for Huntington's disease and spinocerebellar ataxias, and expand the company's VICOMER RNA modulation platform.PR NewswireVico Therapeutics nomme Scott Schobel, MD, au poste de Directeur médical en chefVico Therapeutics B.V., a Leiden-based genetic medicine company focused on neurology, announced the appointment of Scott Schobel, MD as Chief Medical Officer. Dr. Schobel brings 10 years of drug development experience from Roche, where he led the clinical development of the tominersen program for Huntington's disease and also worked on the gantenerumab program. In his new role, he will lead the advancement of VO659, an antisense oligonucleotide therapy targeting Huntington's disease and spinocerebellar ataxias, toward clinical development and expand the company's VICOMER RNA modulation platform.